Analyst firms · Wolfe Research · KYMR
Wolfe Research KYMR price target and rating history
Kymera Therapeutics Inc. (KYMR) · Health Care
Wolfe Research rates Kymera Therapeutics Inc. (KYMR) Outperform with a $180 price target, as of its latest action on Sep 10, 2026. It has published 4 rating actions on KYMR since February 2024, including 2 upgrades and 1 downgrade. Across 5 firms with a KYMR price target in the last 12 months, the median target is $133. Wolfe Research's $180 is 35% above that.
- Current rating
- Outperform
- Price target
- $180
- Median target, all firms
- $133
- Actions on KYMR
- 4
Wolfe Research price target on KYMR
Every Wolfe Research rating on KYMR
- Sep 10, 2026
- Jan 6, 2026
- Aug 26, 2024
- Feb 15, 2024
How other firms rate KYMR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $140 | Oct 9, 2026 |
| Wolfe Research | Outperform | $180 | Sep 10, 2026 |
| Deutsche Bank | Hold | $120 | Jul 30, 2026 |
| Canaccord Genuity | Buy | $106 | May 6, 2026 |
| Jefferies | Buy | Mar 16, 2026 | |
| Barclays | Overweight | $133 | Jan 28, 2026 |
Questions about Wolfe Research and KYMR
- What is Wolfe Research's price target for KYMR?
- Wolfe Research's latest stated price target for Kymera Therapeutics Inc. (KYMR) is $180, from its action on Sep 10, 2026.
- What is Wolfe Research's rating on KYMR?
- Wolfe Research rates KYMR Outperform, a bullish rating, as of Sep 10, 2026.
- When did Wolfe Research last change its view on KYMR?
- On Sep 10, 2026, Wolfe Research upgrades to Outperform from Peer Perform, price target $180.
- How does Wolfe Research's KYMR target compare with other analysts?
- Across 5 firms with a KYMR price target in the last 12 months, the median target is $133. Wolfe Research's $180 is 35% above that.
More KYMR rating histories
All Wolfe Research ratingsKYMR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.